Skip To Main Content
Ariette van Strien on Muck Rack

Ariette van Strien

As seen in: Clinical Leader, Pharma's Almanac
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ariette

Contact Ariette, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

10.12.22 -- Will DCTs Displace The Traditional Trial Model?

|
By Omar Perez, David Amato, Ariette van Strien, Crista Casey
| Clinical Leader Verified
Welcome to the Wednesday edition of the Clinical Leader newsletter, focusing on Decentralized Trials and Trial Management. Update your topic preferences to receive additional Clinical Leader newsletters on: Clinical Sites | Patient Centricity | Patient Recruitment (Monday) Clinical Trial Technology (Tuesday) Outsourcing Models | Regulatory & Compliance (Thursday) (Friday)
Open in Who Shared Issue with article?

06.15.22 -- How Can We Investigate Biomarkers For Lung Cancer Patients More Effectively?

|
By Ofer Sharon, Kevin Duffy, Ariette van Strien, Armand Czaplinski
| Clinical Leader Verified
By Ofer Sharon, OncoHost With a five-year mortality rate of nearly 90%, lung cancer is in dire need of targeted control interventions. There is a serious lack of sufficient predictive biomarkers, turning the lung cancer journey into one in which the patient and physician alike may as well be wearing blindfolds. This article discusses how we can start to swing the needle in the patient's favor.
Open in Who Shared Issue with article?

Facilitating Complex Clinical Trials For Rare Diseases

|
By Ariette van Strien
| Pharma's Almanac Verified
Developing drugs to treat diseases creates opportunities to simultaneously address the urgent unmet medical needs of patient populations and access new markets. The challenging clinical trials landscape for drugs continues to achieve new efficiencies due, in part, to streamlined regulatory processes, decentralized clinical trials models and next-generation technologies, all supported by a flexible and evolving supply chain.
Open in Who Shared Issue with article?
See all 4 articles